Cardiome Pharma Corp. announced that its subsidiary, Correvio GmbH, has entered into an agreement with Sweden based, Tamro AB, to distribute Brinavess (vernakalant IV) to customers in the Swedish market.

“We are delighted to have entered into this distribution agreement with Tamro, a leader in pharmaceutical distribution in Sweden,” said Karim Lalji, Cardiome’s chief commercial officer. “Our agreement will allow orders for Brinavess to be rapidly fulfilled and shipped to hospital customers. Coupled with the positive real-world effectiveness data from Skåne University Hospital in Malmö, Sweden that demonstrated conversion to normal sinus rhythm in approximately 70 per cent of patients treated with Brinavess who were experiencing atrial fibrillation of less than 48 hours duration, we expect Sweden will be a key market for Brinavess growth.

“We are pleased to provide our logistics services and to distribute Brinavess on Cardiome’s behalf to Swedish hospital customers,” said Pontus Moberg, Tamro’s general counsel. “Our strong relationships with hospital customers, deep expertise in pharmaceutical distribution, and highly sophisticated logistics operations will ensure Brinavess customers have a seamless ordering and shipping experience.”

Financial details of the agreement have not been disclosed.

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.